An E-platform for Learners

Pharm'Up

An E-platform for Pharma Learners

HYMPAVZI Significantly Reduces Bleeding in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Shows

HYMPAVZI Significantly Reduces Bleeding in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Shows

Pharm'Up

Pfizer has announced highly promising results from its Phase 3 BASIS clinical trial (NCT03938792), highlighting the efficacy...

New MRI Technique Maps Brain Metabolism to Detect Neurological Disease Signatures

New MRI Technique Maps Brain Metabolism to Detect Neurological Disease Signatures

Pharm'Up

In a major advancement for brain imaging, scientists at the University of Illinois Urbana-Champaign have developed a...

BACE1 Protein Unlocks New Treatment Potential for Lung Cancer Brain Metastasis

BACE1 Protein Unlocks New Treatment Potential for Lung Cancer Brain Metastasis

Pharm'Up

In a groundbreaking scientific advancement, a collaborative team from McMaster University, Cleveland Clinic, and the Case Comprehensive...

RINVOQ Delivers Hopeful Outcomes in Alopecia Areata Study

RINVOQ Delivers Hopeful Outcomes in Alopecia Areata Study

Pharm'Up

AbbVie has released encouraging topline results from Study 2 of the Phase 3 UP-AA clinical program, assessing...

FDA Approves VIZZ: A Breakthrough Eye Drop for Presbyopia Treatment

FDA Approves VIZZ: A Breakthrough Eye Drop for Presbyopia Treatment

Pharm'Up

LENZ Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for...

Merck’s Winrevair™ Gains FDA Priority Review Following Stellar ZENITH Trial Data

Merck’s Winrevair™ Gains FDA Priority Review Following Stellar ZENITH Trial Data

Pharm'Up

Merck has revealed that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review...

Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

Pharm'Up

Novartis has disclosed the preliminary findings from its Phase III GCAptAIN study, assessing Cosentyx® (secukinumab) for the...

Lupin Introduces Ipratropium Bromide Nasal Spray in the U.S. Market

Lupin Introduces Ipratropium Bromide Nasal Spray in the U.S. Market

Pharm'Up

Global pharmaceutical leader Lupin Limited has unveiled the launch of Ipratropium Bromide Nasal Solution (Nasal Spray) in...

Biocon Biologics Gains UK Approval for Denosumab Biosimilars

Biocon Biologics Gains UK Approval for Denosumab Biosimilars

Pharm'Up

Biocon Biologics Ltd. (BBL), a leading global biosimilars company and subsidiary of Biocon Ltd., has received marketing...

Global Heart Disease Toll Linked to Widespread Plastic Chemical Exposure

Global Heart Disease Toll Linked to Widespread Plastic Chemical Exposure

Pharm'Up

A comprehensive study by NYU Langone Health revealed a significant link between daily exposure to di-2-ethylhexyl phthalate...